Synatra™

 Our flow cytometry testing is performed on the Beckman Coulter DX Flex platform using ClearLLab™ reagents, an FDA-approved system designed for precision and reliability. This advanced technology enables rapid immunophenotyping for leukemia, lymphoma, and other hematologic malignancies, delivering high sensitivity and specificity through streamlined workflows. Most cases are completed within a 12–24 hour turnaround time to support timely clinical decision-making. 

 Comprehensive morphologic evaluation is supported by a broad antibody panel tailored specifically for hematopathology. Immunohistochemistry (IHC) and special stains enhance lineage determination and provide essential tools for accurate subclassification of neoplastic diseases. Together, these diagnostic approaches ensure clarity and confidence in complex case evaluation. 

 FISH is a highly sensitive technique used to detect specific genetic abnormalities at the chromosomal level. By using fluorescent probes to identify gene rearrangements, amplifications, and deletions, FISH provides critical diagnostic and prognostic information for hematologic malignancies and solid tumors. These insights help guide accurate diagnosis, risk stratification, and targeted treatment decisions. 

 Our molecular diagnostics testing identifies clinically significant genetic mutations associated with cancer and other diseases. Using advanced PCR-based and targeted molecular techniques, we detect actionable biomarkers that support diagnosis, prognosis, and personalized therapy selection. This precise genetic information enables clinicians to make more informed treatment decisions and improve patient outcomes. 

 Cytogenetic analysis evaluates the structure and number of chromosomes to identify abnormalities associated with malignancies and genetic disorders. Through conventional karyotyping and specialized techniques, our cytogenetics team detects chromosomal gains, losses, and rearrangements that are essential for diagnosis, classification, and prognostic assessment—particularly in leukemia, lymphoma, and bone marrow disorders. 

 Next-Generation Sequencing (NGS) provides comprehensive analysis of multiple genes simultaneously to identify clinically relevant mutations. This powerful technology enables detection of actionable genomic alterations that support precise diagnosis, prognostic evaluation, and targeted therapy selection. NGS plays a critical role in advancing personalized medicine and improving cancer care.